Literature DB >> 21330405

Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Falko Nagel1, Christian Doll, Florian Pöll, Andrea Kliewer, Helmut Schröder, Stefan Schulz.   

Abstract

The clinically used somatostatin (SS-14) analogs octreotide and pasireotide (SOM230) stimulate distinct species-specific patterns of sst(2A) somatostatin receptor phosphorylation and internalization. Like SS-14, octreotide promotes the phosphorylation of at least six carboxyl-terminal serine and threonine residues, namely S341, S343, T353, T354, T356, and T359, which in turn leads to a robust endocytosis of both rat and human sst(2A) receptors. Unlike SS-14, pasireotide fails to induce any substantial phosphorylation or internalization of the rat sst(2A) receptor. Nevertheless, pasireotide is able to stimulate a selective phosphorylation of S341 and S343 of the human sst(2A) receptor followed by a clearly detectable receptor sequestration. Here, we show that transplantation of amino acids 1-180 of the human sst(2A) receptor to the rat sst(2A) receptor facilitates pasireotide-induced internalization. Conversely, construction of a rat-human sst(2A) chimera conferred resistance to pasireotide-induced internalization. We then created a series of site-directed mutants leading to the identification of amino acids 27, 30, 163, and 164 that when exchanged to their human counterparts facilitated pasireotide-driven S341/S343 phosphorylation and internalization of the rat sst(2A) receptor. Exchange of these amino acids to their rat counterparts completely blocked the pasireotide-mediated internalization of the human sst(2A) receptor. Notably, octreotide and SS-14 stimulated a full phosphorylation and internalization of all mutant sst(2A) receptors tested. Together, these findings suggest that pasireotide activates the sst(2A) receptor via a molecular switch that is structurally and functionally distinct from that turned on during octreotide-driven sst(2A) activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330405      PMCID: PMC5417258          DOI: 10.1210/me.2010-0407

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  23 in total

Review 1.  Conformational complexity of G-protein-coupled receptors.

Authors:  Brian K Kobilka; Xavier Deupi
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

2.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Authors:  Renzo Cescato; Kimberly A Loesch; Beatrice Waser; Helmut R Mäcke; Jean E Rivier; Jean Claude Reubi; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2009-11-12

3.  Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.

Authors:  S Schulz; S U Pauli; S Schulz; M Händel; K Dietzmann; R Firsching; V Höllt
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

4.  Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Authors:  S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; A J Farrall; S Melmed; B M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

Review 5.  Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

Authors:  Kjell E Oberg; Jean-Claude Reubi; Dik J Kwekkeboom; Eric P Krenning
Journal:  Gastroenterology       Date:  2010-07-13       Impact factor: 22.682

6.  Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes.

Authors:  Giovanni Tulipano; Ralf Stumm; Manuela Pfeiffer; Hans-Jürgen Kreienkamp; Volker Höllt; Stefan Schulz
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

7.  Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation.

Authors:  Qisheng Liu; Mark S Bee; Agnes Schonbrunn
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

Review 8.  The structure and function of G-protein-coupled receptors.

Authors:  Daniel M Rosenbaum; Søren G F Rasmussen; Brian K Kobilka
Journal:  Nature       Date:  2009-05-21       Impact factor: 49.962

9.  Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.

Authors:  Jochen Mundschenk; Nicole Unger; Stefan Schulz; Volker Höllt; Solveig Schulz; Rainer Steinke; Hendrik Lehnert
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

Review 10.  Conformational changes involved in G-protein-coupled-receptor activation.

Authors:  Jürgen Wess; Sung-Jun Han; Soo-Kyung Kim; Kenneth A Jacobson; Jian Hua Li
Journal:  Trends Pharmacol Sci       Date:  2008-10-04       Impact factor: 14.819

View more
  14 in total

Review 1.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling.

Authors:  Florian Pöll; Christian Doll; Stefan Schulz
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

6.  Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor.

Authors:  Aline Petrich; Anika Mann; Andrea Kliewer; Falko Nagel; Anne Strigli; Jan Carlo Märtens; Florian Pöll; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2013-02-15

7.  Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.

Authors:  L E A Wildemberg; L Vieira Neto; D F Costa; L E Nasciutti; C M Takiya; L M Alves; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2011-09-06       Impact factor: 4.256

Review 8.  Regulated Control of Melanin-Concentrating Hormone Receptor 1 through Posttranslational Modifications.

Authors:  Yumiko Saito; Akie Hamamoto; Yuki Kobayashi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-21       Impact factor: 5.555

Review 9.  Neuroendocrine tumor theranostics.

Authors:  Yasushi Ichikawa; Noritoshi Kobayashi; Shoko Takano; Ikuma Kato; Keigo Endo; Tomio Inoue
Journal:  Cancer Sci       Date:  2022-04-11       Impact factor: 6.518

10.  Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation.

Authors:  Ying Peng; Lili Deng; Yuedi Ding; Quancheng Chen; Yu Wu; Meilin Yang; Yaping Wang; Qiang Fu
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.